Company news
Luye Pharma Group Ltd. news in 2025
Luye Pharma Group Ltd.'s news releases, calls and decks from 2025, newest first.
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
November 24, 2025
Luye Pharma Announces 2025 Half-Year Results
August 29, 2025
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
August 18, 2025
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
August 3, 2025
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
April 10, 2025
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of...
April 6, 2025
Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
January 15, 2025